Eascra Biotech was awarded a 796 million dollar NASA activity.
Published
Signal category
Presence & Recognition
Quote
“NASA's Kevin Engelbert , International Space Station National Laboratory, Massachusetts Biomedical Initiatives (MBI), MassBio, MassVentures, and so many others that it is hard to fit them all in this post.”
— Mari Anne Snow|Eascra Biotech team
Company
Eascra Biotech
Building the next generation of innovative therapeutic nanotechnologies
- Industry
- Biotechnology Research
- Location
- Boston, US
- Company size
- 7 employees
Based on DNA nanotechnology, our novel family of Janus base nanomaterials provides highly effective, super biocompatible solutions that enable enhanced therapeutic delivery and regenerative medicine for articular cartilage, central nervous system disorders, solid tumors, and other chronic conditions. Our three generations of DNA-inspired nanotubes are a cost-effective alternative to existing options, and they have excellent scalability. We can customize our Janus base nanotechnologies to enhance the therapeutic efficacy of drug treatments for a variety of chronic conditions and medical needs.
Founded 2022